The integrin binding peptide, atn-161, as a novel therapy for SARS-CoV-2 infection

Many efforts to design and screen therapeutics for the current severe acute respiratory syndrome coronavirus (SARS-CoV-2) pandemic have focused on inhibiting viral host cell entry by disrupting ACE2 binding with the SARS-CoV-2 spike protein. This work focuses on the potential to inhibit SARS-CoV-2 e...

Full description

Autores:
Tipo de recurso:
Article of investigation
Fecha de publicación:
2020
Institución:
Universidad de Bogotá Jorge Tadeo Lozano
Repositorio:
Expeditio: repositorio UTadeo
Idioma:
eng
OAI Identifier:
oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/14657
Acceso en línea:
https://doi.org/10.1016/j.jacbts.2020.10.003
http://hdl.handle.net/20.500.12010/14657
Palabra clave:
COVID-19
SARS-CoV-2
ACE2
Alpha5beta1 integrin
ATN-161
Therapeutic
Host-cell entry
Viral spike protein
Receptor binding domain
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
Rights
License
Abierto (Texto Completo)